Advertisement

Related Videos

Deborah Collyar: What's In It for Patients?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Advertisement

Advertisement




Nov
21
Today In Oncology
Could Opportunistic Salpingectomy Prevent Ovarian Cancer in Postreproductive Women
Large AI Breast Cancer Screening Trial Increases Detection Rate
Addition of Durvalumab to BCG After TURBT for BCG-Naive, High-Risk NMIBC
Geriatric Assessment–Guided Approach to Treatment Intensity in Older Adults With Acute Myeloid Leukemia
Reducing the Barriers to Receiving CAR T-Cell Therapy for Patients With Hematologic Malignancies
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo